📚 Hepatology — L7: Liver Cirrhosis & Portal Hypertension

📚 Lecture Overview

This lecture covers the pathophysiology, classification, clinical manifestations, complications, and comprehensive management of liver cirrhosis and portal hypertension, with a special focus on esophageal and gastric varices. Understanding these mechanisms is crucial for recognizing hepatic decompensation, diagnosing vascular abnormalities, and managing life-threatening complications.

🎯 Key Concepts & Definitions

• Cirrhosis: A diffuse anatomical process characterized by fibrosis and regenerative nodule formation, disrupting normal liver architecture.
• Clinically Significant Portal Hypertension (CSPH): An Hepatic Venous Pressure Gradient (HVPG) $≥ 10$ mmHg, marking the development of varices and a higher risk of decompensation.
• Compensated Cirrhosis: The absence of clinical complications of hepatic decompensation; patients are typically asymptomatic.
• Decompensated Cirrhosis: A symptomatic disease state marked by manifestations of liver failure such as ascites, hepatic encephalopathy, or coagulopathy.
• Acute-on-Chronic Liver Failure (ACLF): Acute hepatic decompensation in pre-existing chronic liver disease associated with multiorgan failure and high short-term mortality.
• Capillarization of Sinusoids: Loss of endothelial cell fenestrations and hepatocyte microvilli, impeding metabolic exchange.
• Hepatopulmonary Syndrome (HPS): A triad of liver disease/portal hypertension, elevated alveolar-arterial oxygen gradient, and intrapulmonary vasodilatation/shunts.
• Hypersplenism: Spleen overactivity resulting in rapid destruction of blood cells, leading to pancytopenia and splenomegaly.
• HVPG (Hepatic Venous Pressure Gradient): The gold standard measurement for assessing portal hypertension via hepatic vein catheterization; an HVPG <12 mmHg or >20% reduction significantly reduces bleeding risk.
• EBL (Endoscopic Variceal Band Ligation): The preferred endoscopic technique of placing rubber bands around large varices to induce ischemic necrosis and obliteration.
• TIPS (Transjugular Intrahepatic Portosystemic Shunt): A radiological procedure creating a stent shunt between the intrahepatic portal vein and a hepatic vein, used as rescue therapy or a bridge to liver transplantation.

📖 Main Content

Pathogenesis of Cirrhosis and Portal Hypertension

• Hepatic injury leads to hepatocellular necrosis, activating hepatic stellate cells (HSCs) to transform into myofibroblasts.
• HSCs deposit collagen in the Space of Disse (collagenosis), leading to the capillarization of sinusoids.
• Portal hypertension (PH) develops from a combination of:
• Mechanical/Structural Component: Irreversible distortion from fibrosis, regenerative nodules, and collagen.
• Dynamic Component: Reversible intrahepatic vasoconstriction from increased vasoconstrictors (endothelin-1, angiotensin II) and decreased vasodilators (nitric oxide).
• Increased Portal Inflow: Splanchnic arteriolar vasodilation driven by endogenous vasodilators and bacterial translocation.

Portosystemic Collaterals Classification

• Group I: Divided into site Ia (cardiac/stomach: left gastric veins anastomosing with esophageal/azygos veins causing esophageal and gastric varices) and site Ib (anus: superior hemorrhoidal vein anastomosing with middle/inferior hemorrhoidal veins causing rectal varices).
• Group II: Located in the falciform ligament, channeling blood through umbilical/paraumbilical veins to anterior abdominal wall epigastric veins (caput medusae).
• Group III: Occurs where intraperitoneal organs contact retroperitoneal tissues or the abdominal wall.
• Group IV: Carries portal blood directly to the left renal vein from the splenic vein (splenorenal shunt) or gastric veins (gastrorenal shunt).

Clinical Manifestations & Complications

• Portal Hypertension Manifestations: Portosystemic shunts (variceal bleeding, caput medusa), splenomegaly (hypersplenism), and ascites.
• Hepatic Decompensation Events:
• Ascites: Fluid accumulation in the peritoneal cavity due to vasodilation and transudation.
• Hepatic Encephalopathy (HE): Characterized by fetor hepaticus, asterixis (flapping tremors), and altered consciousness.
• Coagulopathy: Bleeding tendencies due to deficient synthesis of clotting factors.
• Endocrine & Vascular Changes: Spider angiomas, palmar erythema, gynecomastia, and testicular atrophy resulting from hyperestrogenemia.
• Cardiopulmonary Complications:
• Hyperdynamic Circulatory Syndrome: Increased cardiac output and systemic vasodilation.
• Cirrhotic Cardiomyopathy: Cardiac dysfunction unmasked during stress.
• Portopulmonary Hypertension: Pulmonary arterial hypertension associated with portal hypertension.
• Hepatopulmonary Syndrome: Oxygenation defect due to intrapulmonary vascular dilatation and AV shunts, presenting with platypnea and orthodeoxia.

Diagnosis & Assessment

• Gold Standard: Liver biopsy (transjugular route used if ascites or coagulopathy is present).
• Imaging: Ultrasound (screening tool for HCC every 6 months), CT, and MRI. Doppler US measures blood flow and detects thrombosis.
• Non-Invasive Tests: APRI, FIB-4 index, and Vibration-Controlled Transient Elastography (FibroScan) measuring liver stiffness in kilopascals (kPa).
• Prognostic Scores:
• Child-Pugh Classification: Uses ascites, encephalopathy, albumin, bilirubin, and prothrombin time (Classes A, B, and C).
• MELD Score: Uses creatinine, INR, and bilirubin (plus sodium in MELDNa) to predict mortality and organ allocation.
• Laboratory Findings: Thrombocytopenia (platelet count <150 $×$ $10^3$/dL) combined with liver stiffness measurement strongly suggests PH.

Management & Treatment Strategies

• General Measures: High-calorie diet, adequate protein (1.2–1.5 g/kg/day), sodium restriction for ascites, avoidance of sedatives and proton pump inhibitors, and vaccinations for Hepatitis A/B, pneumococcal, and influenza.
• Pharmacological Therapy:
• Vasoconstrictors (Short-Term): Terlipressin (vasopressin analog acting on V1 receptors) and octreotide (somatostatin analog inhibiting splanchnic vasodilatory hormones) are used for acute bleeding episodes.
• Non-Selective Beta-Blockers (NSBBs - Long-Term): Traditional agents like propranolol and nadolol reduce cardiac output and splanchnic blood flow.
• Carvedilol: A potent NSBB with alpha-1 receptor blockade properties that lowers intrahepatic vascular resistance in addition to reducing blood flow, making it superior for HVPG reduction.
• Endoscopic and Surgical Management:
• Endoscopic Variceal Band Ligation (EBL): Preferred over injection sclerotherapy due to lower complication rates and faster variceal eradication.
• Cyanoacrylate Injection: Tissue adhesive used for rapid polymerization and obliteration of gastric varices.
• Surgical Shunts & TIPS: Decompressive shunts and TIPS (stent connecting portal and hepatic veins) are utilized for refractory bleeding or as bridges to liver transplantation.
• Etiological Treatment: Antivirals for viral hepatitis, alcohol abstinence, immunosuppressants for autoimmune hepatitis, and chelation for Wilson disease.

📊 Visual Learning

💡 Important Points to Remember

• HVPG Thresholds: Normal $≤ 5$ mmHg; subclinical PH is $5-10$ mmHg; Clinically Significant Portal Hypertension (CSPH) is $≥ 10$ mmHg. Target HVPG reduction is $>20%$ or $<12$ mmHg.
• Fibrosis Zones: Viral hepatitis and hemochromatosis cause fibrosis in Zone 1 (periportal); alcoholism and right heart failure cause fibrosis in Zone 3.
• Child-Pugh Parameters: Ascites, Encephalopathy, Albumin, Bilirubin, and Prothrombin Time (AE-ABP).
• MELD Score Parameters: Creatinine, INR, and Bilirubin (CIB).
• HPS Triad: Liver disease/PH, elevated $AaPO_2$ gradient, and intrapulmonary vasodilatation/shunts.
• Platypnea & Orthodeoxia: Classic signs of Hepatopulmonary Syndrome where dyspnea and hypoxia worsen in the upright position.
• Platelet Count Clue: A platelet count <150 $×$ $10^3$/dL combined with liver stiffness $≥$20 kPa identifies high-risk varices requiring screening.
• Terlipressin vs. Octreotide: Terlipressin binds V1 receptors for systemic/splanchnic vasoconstriction; octreotide inhibits splanchnic vasodilatory hormones.
• Carvedilol Advantage: Combines beta-1/2 blockade with alpha-1 blockade, reducing both blood flow and intrahepatic resistance.
• Common Trap (PPIs): Avoid unnecessary Proton Pump Inhibitors; they increase the risk of gut dysbiosis, SBP, and hepatic encephalopathy.
• Common Trap (Beta-Blockers in Acute Bleed): NSBBs must be avoided during active acute variceal bleeding episodes.
• AST/ALT Ratio: AST is typically greater than ALT (AST > ALT) in cirrhosis due to mitochondrial injury and decreased clearance.

⚠️ Common Exam Questions

• MCQ Trick 1: Examiners often ask which complication is not a sign of first decompensation, confusing incidental findings (like mild asymptomatic varices found on scope) with true decompensation events (ascites, variceal bleed, overt HE).
• MCQ Trick 2: Testing whether beta-blockers should be continued during acute variceal bleeding. The correct answer is NO; they must be avoided during an acute bleed.
• Short Answer: Expect questions asking to differentiate the mechanical (fixed) versus dynamic (reversible) components of portal hypertension and which one pharmacological treatments target (dynamic component via vasodilation/HSC relaxation).
• Clinical Vignette Trap 1: A patient with cirrhosis presenting with sudden worsening of dyspnea upon standing up (platypnea-orthodeoxia). Students often mistake this for pulmonary embolism or cardiac failure, whereas it points directly to Hepatopulmonary Syndrome.
• Clinical Vignette Trap 2: A patient presenting with gastric varices and a large splenorenal shunt, suggesting cyanoacrylate glue injection. The trap is ignoring the contraindication: glue can cause pulmonary/cerebral embolism in these shunts.

📝 Quick Review Checklist

I can define liver cirrhosis and its morphological classifications
I understand the pathogenesis involving hepatic stellate cells and sinusoidal capillarization
I can differentiate between compensated and decompensated cirrhosis
I know the hemodynamic thresholds for Clinically Significant Portal Hypertension (CSPH)
I can list the parameters used in the Child-Pugh and MELD scoring systems
I can explain the classification and anatomy of portosystemic collaterals
I understand the cardiopulmonary complications including HPS and portopulmonary hypertension
I know the indications and mechanisms of pharmacological therapies (terlipressin, octreotide, carvedilol)
I understand the management principles for variceal bleeding, EBL, and hepatic encephalopathy
I know when to utilize TIPS as a rescue therapy or bridge to transplantation